Showing 5051-5060 of 5963 results for "".
- Survey Highlights Risks of Pubic Hair Groominghttps://practicaldermatology.com/news/survey-highlights-risks-of-pubic-hair-grooming/2458086/More than one-quarter of people who groom their pubic hair sustain grooming-related injuries, according to a new article published by JAMA Dermatology. Of the 7,570 men and women who completed
- New Criteria Aims to Help Doctors Spot Amelanotic Melanoma Earlierhttps://practicaldermatology.com/news/new-criteria-aims-to-help-doctors-spot-amelanotic-melanoma-earlier/2458092/New research outlines key features linked to amelanotic melanoma. The findings, which appear in JAMA Dermatology, may help improve detection of this type of melanoma, which is more likely to be diagnosed at advanced stages because it falls outside of the “ABCDE” guide
- Review Study Suggests Vitamin B3 May Prevent Melanomahttps://practicaldermatology.com/news/review-study-suggests-vitamin-b3-may-prevent-melanoma/2458093/Nicotinamide (Vitamin B3) may help stave off melanoma in high-risk individuals, a new review study suggests. “Nicotinamide has been shown in a clinical trial—called ONTRAC—to reduce the incidence of non-melanoma skin cancer in high-risk individuals and it would be worthw
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz
- Modernizing Medicine To Add More Than 800 Jobs in Expansionhttps://practicaldermatology.com/news/modernizing-medicine-to-add-more-than-800-jobs-in-expansion/2458101/Modernizing Medicine will expand operations and add a total of 838 jobs by 2022. The expansion, to be implemented in the historic Boca Raton Innovation Center (BRIC) in Palm Beach County will result in a capital investment of more than $15 million in the Boca Raton community.
- MKTP Surgery Shows Long-Term Benefit for Restoring Skin Pigmentation in Vitiligohttps://practicaldermatology.com/news/mktp-surgery-shows-long-term-benefit-for-restoring-skin-pigmentation-in-vitiligo/2458103/Melanocyte-keratinocyte transplantation (MKTP) provides long-term benefits for restoring skin pigmentation caused by vitiligo, report researchers from Henry Ford Hospital in Detroit. “MKTP works and it lasts a long time,” says Iltefat Hamzavi, M.D., a Henry Ford dermatologist
- Cutanea Life Sciences Unveils Facing Forward Mobile App for Acne Patientshttps://practicaldermatology.com/news/cutanea-life-sciences-unveils-facing-forward-new-mobile-app-for-acne-patients/2458104/Cutanea Life Sciences, Inc. introduced its Facing Forward mobile application for patients who are prescribed Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The app will be available free thro
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- Joseph H. Boccuzi Appointed to Allergan plc Board of Directorshttps://practicaldermatology.com/news/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors/2458116/Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with